|
Genes over-expressed in JRA neutrophils |
|||||
| GenBank accession no. |
Symbol |
Description |
Avg. control |
Avg. patients |
Ratio P/C |
|
|
|||||
| NM_001124 |
ADM |
Adrenomedullin |
0.3 |
3.2 |
10.3 |
| NM_001706 |
BCL6 |
B-cell CLL/lymphoma 6 (zinc finger protein 51) |
54.0 |
179.9 |
3.3 |
| NM_001729 |
BTC |
Betacellulin |
0.2 |
2.8 |
12.1 |
| NM_001295 |
CCR1 |
Chemokine (C-C motif) receptor 1 |
1.5 |
5.6 |
3.7 |
| NM_001785 |
CDA |
Cytidine deaminase |
10.9 |
30.6 |
2.8 |
| NM_004360 |
CDH1 |
Cadherin 1, type 1, E-cadherin (epithelial) |
0.3 |
2.2 |
6.4 |
| NM_005194 |
CEBPB |
CCAAT/enhancer binding protein (C/EBP), beta |
1.1 |
3.7 |
3.2 |
| NM_000651 |
CR1 |
Complement component (3b/4b) receptor 1, including Knops blood group system |
6.6 |
21.3 |
3.2 |
| AF172398 |
F11R |
F11 receptor, JAM1 |
0.5 |
3.5 |
7.2 |
| NM_002005 |
FES |
Feline sarcoma oncogene |
35.6 |
108.3 |
3.0 |
| NM_001462 |
FPRL1 |
Formyl peptide receptor-like 1 |
21.0 |
72.0 |
3.4 |
| NM_000637 |
GSR |
Glutathione reductase |
3.7 |
18.5 |
5.0 |
| NM_015401 |
HDAC7A |
Histone deacetylase 7A |
3.3 |
9.7 |
2.9 |
| NM_002127 |
HLA-G |
HLA-G histocompatibility antigen, class I, G |
336.2 |
956.2 |
2.8 |
| NM_005345 |
HSPA1A |
Heat shock 70-kDa protein 1A |
20.6 |
53.7 |
2.6 |
| NM_014339 |
IL17R |
Interleukin 17 receptor |
10.2 |
28.5 |
2.8 |
| NM_000634 |
IL8RA |
Interleukin 8 receptor, alpha |
13.6 |
53.9 |
4.0 |
| BC017197 |
MCL1 |
Myeloid cell leukemia sequence 1 (BCL2-related) |
5.3 |
21.5 |
4.1 |
| NM_007289 |
MME |
Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) |
9.5 |
29.5 |
3.1 |
| NM_013416 |
NCF4 |
Neutrophil cytosolic factor 4 (40 kDa) |
20.0 |
58.6 |
2.9 |
| AF171938 |
NUMB |
Numb homolog (Drosophila) |
3.2 |
11.6 |
3.7 |
| NM_023914 |
P2RY13 |
purinergic receptor P2Y, G-protein coupled, 13, GPR86 |
8.7 |
32.0 |
3.7 |
| NM_014143 |
PDCD1LG1 |
programmed cell death 1 ligand, B7-H1 |
0.3 |
5.1 |
15.3 |
| NM_000442 |
PECAM1 |
Platelet/endothelial cell adhesion molecule (CD31 antigen) |
6.2 |
12.5 |
2.0 |
| NM_001198 |
PRDM1 |
PR domain containing 1, with ZNF domain |
0.8 |
6.8 |
8.9 |
| NM_000962 |
PTGS1 |
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
0.3 |
8.6 |
29.5 |
| NM_002838 |
PTPRC |
Protein tyrosine phosphatase, receptor type, C |
55.9 |
159.7 |
2.9 |
| NM_002881 |
RALB |
V-ral simian leukemia viral oncogene homolog B (ras related-GTP binding protein) |
5.2 |
15.8 |
3.0 |
| NM_004761 |
RGL2 |
ral guanine nucleotide dissociation stimulator-like 2, RAB2 |
3.0 |
8.9 |
3.0 |
| NM_005621 |
S100A12 |
S100 calcium binding protein A12 (calgranulin C) |
62.9 |
164.0 |
2.6 |
| NM_002964 |
S100A8 |
S100 calcium binding protein A8 (calgranulin A) |
791.4 |
2,017.6 |
2.5 |
| NM_002965 |
S100A9 |
S100 calcium binding protein A9 (calgranulin B) |
1,152.7 |
2,697.1 |
2.3 |
| D83782 |
SCAP |
SREBP CLEAVAGE-ACTIVATING PROTEIN |
0.3 |
2.6 |
7.5 |
| NM_022464 |
SIL1 |
Endoplasmic reticulum chaperone SIL1, homolog of yeast |
0.3 |
5.0 |
14.9 |
| NM_004171 |
SLC1A2 |
Solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
7.5 |
32.9 |
4.4 |
| NM_001045 |
SLC6A4 |
Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
22.8 |
44.5 |
2.0 |
| NM_003105 |
SORL1 |
Sortilin-related receptor, L(DLR class) A repeats-containing |
31.9 |
89.7 |
2.8 |
| NM_003153 |
STAT6 |
Signal transducer and activator of transcription 6, interleukin-4 induced |
1.6 |
7.9 |
5.0 |
| NM_003263 |
TLR1 |
Toll-like receptor 1 |
10.4 |
28.6 |
2.8 |
| NM_003841 |
TNFRSF10C |
Tumour necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain |
8.9 |
39.6 |
4.5 |
| NM_006573 |
TNFSF13B |
Tumour necrosis factor (ligand) superfamily, member 13b |
9.2 |
22.4 |
2.4 |
| NM_003329 |
TXN |
Thioredoxin |
9.0 |
24.8 |
2.8 |
|
Avg. control, average (normalised) intensity in controls; Avg. patients = average (normalised) intensity in patients; Ratio P/C, fold difference between patients and controls. | |||||
Jarvis et al. Arthritis Research & Therapy 2006 8:R154 doi:10.1186/ar2048 |
|||||